Brachytherapy Gives ‘Excellent’ Results Post-lumpectomy
January 1st 1999PHOENIX-Five-year results of a pilot study at the Ochsner Clinic, New Orleans, suggests that a 4-day course of brachytherapy may be just as effective as a 6-week course of external beam radiation therapy in breast cancer patients who have undergone breast-conserving surgery.
Good Response Durations Seen With Rituximab in NHL
January 1st 1999MIAMI BEACH-Long-term follow-up of the pivotal trial of rituximab (Rituxan) in patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL), shows a median duration of response of nearly 1 year (11.6 months), Peter McLaughlin, MD, reported at a poster session of the American Society of Hematology (ASH) meeting.
NCI Plans Major Restructuring of Clinical Trials Program
January 1st 1999BETHESDA, Md-The National Cancer Institute plans a major restructuring of its clinical trials program, intended to broaden participation by physicians and patients and shorten the time between the initial idea for a treatment study and its conclusion.
Clinical Status and Optimal Use of Amifostine
January 1st 1999An important, though as yet elusive, goal of cancer chemotherapy is the development of agents that are selectively toxic to tumor cells and, thus, permit effective cancer treatment to be administered without severe, often life-threatening toxicity to normal tissues. Until such agents are available, an alternative strategy to improve the therapeutic index of cancer chemotherapy is the administration of cytoprotective agents to selectively protect normal tissues from injury by cytotoxic drugs.
Smoking by Pregnant Teens Trends Upward Again
January 1st 1999HYATTSVILLE, Md-The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.
EORTC DCIS Study Confirms Recurrence Reduction With RT
December 1st 1998FLORENCE, Italy-Radiotherapy reduces the odds of local recurrence in women with ductal carcinoma in situ (DCIS) who have undergone breast-conserving surgery, according to 4-year follow-up evidence from a trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).
Managed Care Sees Need for National Guidelines, Accreditation
December 1st 1998BUFFALO, NY-Cancer care services vary widely among health care plans in the United States, speakers told the President’s Cancer Panel at a meeting hosted by Roswell Park Cancer Institute. Suggestions for helping standardize care included use of outside accreditation centers and adoption of national practice guidelines, although the methodology to be used to develop such guidelines remains open to debate.
Drinking Tea After Smoking May Reduce Oxidative Stress
December 1st 1998WASHINGTON-Forget those smoke-filled cocktail lounges, tobacco addicts, and head for a local tea room. “Drinking tea after smoking reduces levels of oxidative stress,” reported James E. Klaunig, PhD, professor of pharmacology and toxicology, Indiana University School of Medicine. Oxidative stress has been linked to cancer and other diseases .
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHL
December 1st 1998PHOENIX-A single dose of a radiolabeled anti-CD20 monoclonal antibody (MoAB), given following rituximab (Rituxan) dosing, produced responses in two thirds of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL), Gregory Wiseman, MD, of the Mayo Clinic, said at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
Tobacco Industry Settles With States
December 1st 1998WASHINGTON-As Oncology News International went to press, the tobacco industry and more than 40 state attorneys general were in final negotiations of a settlement worth approximately $206 over 25 years. The settlement will reimburse the states for Medicare spending on smoking-related illnesses, place some limits on cigarette advertising, and result in a substantial increase in cigarette prices. Look for a full analysis of the settlement in the January issue.
Full FDA Approval for Camptosar
December 1st 1998ROCKVILLE, Md-The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
Panel Recommends FDA Approval of DepoCyt
December 1st 1998SILVER SPRING, Md-Depo-Tech’s DepoCyt (cytarabine liposome injection) has won the backing of the Oncology Drug Advisory Committee (ODAC), which recommended that the FDA grant the drug accelerated approval for the intrathecal treatment of lympho-matous meningitis. The 6-to-1 vote came about 1 year after ODAC declined to recommend the drug for intrathecal treatment of neoplastic meningitis in patients with solid tumors.
Automated System Provides Fast Delivery of IMRT Plans
December 1st 1998GALVESTON, Tex-Last October, radiation oncologists at the University of Texas Medical Branch in Galveston treated their first patient with intensity modulated radiation therapy (IMRT). The patient received a computer-planned prostate boost involving seven beam angles and 25 beam segments (see Figure). This complex plan allowed for maximum targeting of the tumor while minimizing radiation to the urethra, rectum, and bladder.
Better Biomarkers of Tea’s Effects on Oxidative Stress Needed
December 1st 1998WASHINGTON-Can the humble cup of tea ward off chronic diseases like cancer? Hints of the potential health benefits of tea are intriguing, but the emphasis remains on the “potential,” said Jeffrey B. Blumberg, PhD, chief of the Antioxidants Research Laboratory, Tufts University. He spoke at the Second International Scientific Symposium on Tea and Human Health.
Family Physicians Increasingly Taking Role of Coordinator of Cancer Care, ACS President Says
December 1st 1998SAN FRANCISCO-In an era of increasing fragmentation and specialization in cancer care, and a trend toward ambulatory care, the family physician’s role as a coordinator of care is more important than ever-for both patients and cancer specialists, David Rosenthal, MD, president of the American Cancer Society (ACS), said at the American Academy of Family Physicians meeting.
Groups Use Different Methods in Developing Guidelines
December 1st 1998BUFFALO, NY-Evidence-based practice guidelines are needed to improve the quality of cancer care, several representatives from the professional cancer societies told the President’s Cancer Panel at a meeting hosted by Roswell Park Cancer Institute . But expert physicians also play a critical role in the creation of practice guidelines, particularly in situations where evidence is lacking or controversial.
Teenage Athletes Using Spit Tobacco More Likely to Quit With Intervention
December 1st 1998A new University of California San Francisco (UCSF) study found that high school baseball players who use spit tobacco are nearly twice as likely to stop using spit tobacco when dentists or dental hygienists, as well as their teammates, actively
Investigational Anti-HIV Drug to Be Made Available Through Early Access Program
December 1st 1998The investigational anti-HIV protease inhibitor amprenavir (Agenerase), formerly known as 141W94, is now available to patients who have not responded to current protease inhibitor-containing regimens through a novel early access program.
Management Contract ‘Frees MDs From Business Worries’
December 1st 1998WASHINGTON-About 3½ years ago, in an effort to come to terms with managed care, Dean H. Gesme, Jr., MD, and his partners in a Cedar Rapids, Iowa, oncology practice named Iowa Cancer Care (ICC), entered into a Management Service Organization (MSO) agreement with Physicians Reliance Network, Inc. (PRN), a Texas company. In making this move, they “gave up some autonomy,” in exchange for freedom from dealing with business matters, Dr. Gesme said at a symposium on negotiating contracts in oncology.
NCCN to Present New Guidelines, Outcomes Database
December 1st 1998PHILADELPHIA-With the completion of nine new oncology practice guidelines, to be presented at the fourth annual conference of the National Comprehensive Cancer Network (NCCN), the coalition’s guidelines now cover approximately 95% of cancer patients treated in the United States, William T. McGivney, PhD, chief executive officer of the NCCN, told Oncology News International in an inverview. The NCCN is a consortium of 17 major US cancer centers.
NCI, NIH Both Win Increases of 15% in 1999 Budget
December 1st 1998BETHESDA, Md-Congress has appropriated the National Cancer Institute $2.93 billion for fiscal year 1999, which began Oct. 1, up from $2.54 billion in fiscal year 1998. The $390 million funding increase represents a raise of 15.35% for NCI.
Annual Mammogram Screening Urged for Women in 40s
December 1st 1998WASHINGTON-“There is really no reason to doubt that mammography screening works for women in their 40s,” and saves lives, said Stephen A. Feig, MD, director of the Breast Imaging Center at Thomas Jefferson Hospital and professor of radiology at the Jefferson Medical College, both in Philadelphia.
Reducing Malpractice Risk From False-Negative Pap Smear Tests
December 1st 1998Automated screening of Pap smears provides greater accuracy than traditional manual readings, as discussed in part 2 of this article . As this technology comes into greater use, the standard of care regarding Pap smears may shift, such that a physician’s failure to recommend automated screening could be held against him in a malpractice lawsuit.